Saad Usmani, MD, MBA, FACP, Memorial Sloan Kettering Cancer Center, New York, NY, gives an update on the CARTITUDE-5 study (NCT04923893), which compares the efficacy of bortezomib, lenalidomide and dexamethasone (VRd) induction therapy followed by ciltacabtagene autoleucel (cilta-cel) or lenalidomide and dexamethasone maintenance (Rd) in patients with newly diagnosed multiple myeloma (NDMM) who are transplant-ineligible or that have deferred transplantation until first relapse. The primary endpoint is measurable residual disease (MRD) negativity and secondary endpoints include overall response rate (ORR) and overall survival (OS). The results from this trial are eagerly awaited and could potentially be practice-changing. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
Ещё видео!